Free tool
FAERS Monitor: Jentadueto
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 201281 or its brand name (Jentadueto, Linagliptin, Metformin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,201
Serious
655
55% of reports
Hospitalization
343
Death reported
52
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased93
- diarrhoea90
- nausea67
- vomiting58
- drug ineffective53
- fatigue45
- off label use45
- pain43
- dizziness42
- headache41
- arthralgia40
- acute kidney injury38
- asthenia37
- pain in extremity34
- dyspnoea33
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 38 |
| 2013 | 79 |
| 2014 | 106 |
| 2015 | 118 |
| 2016 | 111 |
| 2017 | 116 |
| 2018 | 109 |
| 2019 | 115 |
| 2020 | 72 |
| 2021 | 82 |
| 2022 | 68 |
| 2023 | 64 |
| 2024 | 62 |
| 2025 | 39 |
| 2026 | 22 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,958 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood glucose increasedSignal | 93 | 8.6 | 7.1 | 627 |
| acute kidney injurySignal | 38 | 4.3 | 3.2 | 95 |
| diarrhoeaSignal | 90 | 2.4 | 2.0 | 78 |
| vomitingSignal | 58 | 2.2 | 1.7 | 36 |
| pain in extremitySignal | 34 | 2.0 | 1.5 | 17 |
| asthenia | 37 | 1.7 | 1.3 | 11 |
| arthralgia | 40 | 1.7 | 1.2 | 11 |
| nausea | 67 | 1.5 | 1.2 | 10 |
| dizziness | 42 | 1.5 | 1.1 | 6 |
| pain | 43 | 1.2 | 0.9 | 2 |
| headache | 41 | 1.1 | 0.8 | 1 |
| dyspnoea | 33 | 1.0 | 0.7 | 0 |
| fatigue | 45 | 1.0 | 0.8 | 0 |
| off label use | 45 | 0.9 | 0.7 | 0 |
| drug ineffective | 53 | 0.7 | 0.5 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.